Literature DB >> 27339073

Increased tauopathy drives microglia-mediated clearance of beta-amyloid.

Wesley Chen1,2, Edsel A Abud1,2, Stephen T Yeung3,4, Anita Lakatos1,3, Trevor Nassi1, Jane Wang1, David Blum5, Luc Buée5, Wayne W Poon3, Mathew Blurton-Jones6,7,8.   

Abstract

Alzheimer disease is characterized by the accumulation of β-amyloid (Aβ) plaques and tau-laden neurofibrillary tangles. Emerging studies suggest that in neurodegenerative diseases, aggregation of one protein species can promote other proteinopathies and that inflammation plays an important role in this process. To study the interplay between Aβ deposition, tau pathology, and microgliosis, we established a new AD transgenic mouse model by crossing 5xfAD mice with Thy-Tau22 transgenic mice. The resulting 'T5x' mice exhibit a greater than three-fold increase in misfolded and hyperphosphorylated tau and further substantiates the hypothesis that Aβ accelerates tau pathology. Surprisingly, T5x mice exhibit a 40-50 % reduction in Aβ plaque load and insoluble Aβ species when compared with aged-matched 5xfAD littermates. T5x mice exhibit significant changes in cytokine production, an almost doubling of microglial number, and a dramatic shift in microglia activation state. Furthermore, T5x microglia exhibit increased phagocytic capacity that enhances the clearance of insoluble Aβ and decreasing plaque load. Therefore, our results suggest that strategies to increase the phagocytic ability of microglia can be employed to reduce Aβ and that tau-induced changes in microglial activation state can promote the clearance of Aβ.

Entities:  

Keywords:  Amyloid; Aβ; Cytokines; Mice; Microglia; Pathology; Phagocytosis; Tau

Mesh:

Substances:

Year:  2016        PMID: 27339073      PMCID: PMC4918195          DOI: 10.1186/s40478-016-0336-1

Source DB:  PubMed          Journal:  Acta Neuropathol Commun        ISSN: 2051-5960            Impact factor:   7.801


  88 in total

1.  Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology.

Authors:  Cyril Laurent; Sabiha Eddarkaoui; Maxime Derisbourg; Antoine Leboucher; Dominique Demeyer; Sébastien Carrier; Marion Schneider; Malika Hamdane; Christa E Müller; Luc Buée; David Blum
Journal:  Neurobiol Aging       Date:  2014-03-29       Impact factor: 4.673

2.  Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease.

Authors:  Ilie-Cosmin Stancu; Laurence Ris; Bruno Vasconcelos; Claudia Marinangeli; Léonie Goeminne; Vincent Laporte; Laetitia E Haylani; Julien Couturier; Olivier Schakman; Philippe Gailly; Nathalie Pierrot; Pascal Kienlen-Campard; Jean-Noël Octave; Ilse Dewachter
Journal:  FASEB J       Date:  2014-03-06       Impact factor: 5.191

3.  Depletion of microglia and inhibition of exosome synthesis halt tau propagation.

Authors:  Hirohide Asai; Seiko Ikezu; Satoshi Tsunoda; Maria Medalla; Jennifer Luebke; Tarik Haydar; Benjamin Wolozin; Oleg Butovsky; Sebastian Kügler; Tsuneya Ikezu
Journal:  Nat Neurosci       Date:  2015-10-05       Impact factor: 24.884

Review 4.  'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease?

Authors:  Kathleen R Zahs; Karen H Ashe
Journal:  Trends Neurosci       Date:  2010-06-09       Impact factor: 13.837

5.  GM-CSF promotes proliferation of human fetal and adult microglia in primary cultures.

Authors:  S C Lee; W Liu; C F Brosnan; D W Dickson
Journal:  Glia       Date:  1994-12       Impact factor: 7.452

6.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

Authors:  J Lewis; D W Dickson; W L Lin; L Chisholm; A Corral; G Jones; S H Yen; N Sahara; L Skipper; D Yager; C Eckman; J Hardy; M Hutton; E McGowan
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

7.  2014 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2014-03       Impact factor: 21.566

8.  Rod microglia: elongation, alignment, and coupling to form trains across the somatosensory cortex after experimental diffuse brain injury.

Authors:  Jenna M Ziebell; Samuel E Taylor; Tuoxin Cao; Jordan L Harrison; Jonathan Lifshitz
Journal:  J Neuroinflammation       Date:  2012-10-30       Impact factor: 8.322

9.  Missense variant in TREML2 protects against Alzheimer's disease.

Authors:  Bruno A Benitez; Sheng Chih Jin; Rita Guerreiro; Rob Graham; Jenny Lord; Denise Harold; Rebecca Sims; Jean-Charles Lambert; J Raphael Gibbs; Jose Bras; Celeste Sassi; Oscar Harari; Sarah Bertelsen; Michelle K Lupton; John Powell; Celine Bellenguez; Kristelle Brown; Christopher Medway; Patrick C G Haddick; Marcel P van der Brug; Tushar Bhangale; Ward Ortmann; Tim Behrens; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg; Jonathan L Haines; Jim Turton; Anne Braae; Imelda Barber; Anne M Fagan; David M Holtzman; John C Morris; Julie Williams; John S K Kauwe; Philippe Amouyel; Kevin Morgan; Andy Singleton; John Hardy; Alison M Goate; Carlos Cruchaga
Journal:  Neurobiol Aging       Date:  2013-12-21       Impact factor: 4.673

10.  Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimer's disease.

Authors:  Véréna Landel; Kévin Baranger; Isabelle Virard; Béatrice Loriod; Michel Khrestchatisky; Santiago Rivera; Philippe Benech; François Féron
Journal:  Mol Neurodegener       Date:  2014-09-11       Impact factor: 14.195

View more
  18 in total

Review 1.  Let's make microglia great again in neurodegenerative disorders.

Authors:  Marie-Victoire Guillot-Sestier; Terrence Town
Journal:  J Neural Transm (Vienna)       Date:  2017-10-12       Impact factor: 3.575

Review 2.  Tau Spread, Apolipoprotein E, Inflammation, and More: Rapidly Evolving Basic Science in Alzheimer Disease.

Authors:  Bianca Gonzalez; Edsel M Abud; Abigail M Abud; Wayne W Poon; Karen H Gylys
Journal:  Neurol Clin       Date:  2017-05       Impact factor: 3.806

Review 3.  Microglia in Alzheimer's Disease: a Key Player in the Transition Between Homeostasis and Pathogenesis.

Authors:  Karen N McFarland; Paramita Chakrabarty
Journal:  Neurotherapeutics       Date:  2022-03-14       Impact factor: 6.088

Review 4.  Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing.

Authors:  Jiansong Fang; Andrew A Pieper; Ruth Nussinov; Garam Lee; Lynn Bekris; James B Leverenz; Jeffrey Cummings; Feixiong Cheng
Journal:  Med Res Rev       Date:  2020-07-13       Impact factor: 12.944

Review 5.  Synergy between amyloid-β and tau in Alzheimer's disease.

Authors:  Marc Aurel Busche; Bradley T Hyman
Journal:  Nat Neurosci       Date:  2020-08-10       Impact factor: 24.884

Review 6.  Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?

Authors:  Fangda Leng; Paul Edison
Journal:  Nat Rev Neurol       Date:  2020-12-14       Impact factor: 42.937

7.  A Study of Amyloid-β and Phosphotau in Plaques and Neurons in the Hippocampus of Alzheimer's Disease Patients.

Authors:  Diana Furcila; Javier DeFelipe; Lidia Alonso-Nanclares
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

8.  The Synthetic Retinoid Acitretin Increases IL-6 in the Central Nervous System of Alzheimer Disease Model Mice and Human Patients.

Authors:  Malena Dos Santos Guilherme; Nicolai M Stoye; Stefan Rose-John; Christoph Garbers; Andreas Fellgiebel; Kristina Endres
Journal:  Front Aging Neurosci       Date:  2019-07-23       Impact factor: 5.750

Review 9.  Clinical PET Imaging of Microglial Activation: Implications for Microglial Therapeutics in Alzheimer's Disease.

Authors:  Zhiwei Shen; Xinjie Bao; Renzhi Wang
Journal:  Front Aging Neurosci       Date:  2018-10-08       Impact factor: 5.750

10.  Distinct Microglial Responses in Two Transgenic Murine Models of TAU Pathology.

Authors:  Carmen Romero-Molina; Victoria Navarro; Raquel Sanchez-Varo; Sebastian Jimenez; Juan J Fernandez-Valenzuela; Maria V Sanchez-Mico; Clara Muñoz-Castro; Antonia Gutierrez; Javier Vitorica; Marisa Vizuete
Journal:  Front Cell Neurosci       Date:  2018-11-14       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.